The pharmaceutical trade group PhRMAhas come out strongly against tariffs, warning that every dollar collected in tariffs means one less dollar invested in U.S. biopharmaceutical research and development.
In a comment submitted to the Department of Commerce, PhRMA Executive Vice President of International Advocacy Jay Taylor advised against enforcing tariffs, saying trade barriers in market should be addressed through “negotiation and enforcement of robust bilateral and sectoral agreements.”
The Commerce Department is currently carrying out an investigation into pharmaceutical and pharmaceutical ingredients imports.
“Recognizing the strength of the innovative biopharmaceutical sector in the United States, Commerce should use this investigation to identify where there are specific national security vulnerabilities (i.e., if the industry is over-reliant on supply for essential medicines and API from adversarial countries) and identify appropriate targeted solutions to address those concerns,” Taylor wrote.
When President Trump unveiled his “reciprocal” tariffs last month, pharmaceutical products were exempted along with other goods like copper and lumber articles.
Contrary to what Trump has claimed, Taylor wrote tariffs are not the key creating more domestic production of goods like pharmaceutical products. Roughly 90 percent of prescriptions in the U.S. are for generic drugs, with India and China being major sources of these medications or their active pharmaceutical ingredients.
“On the contrary, every dollar collected in tariffs would be a dollar less that innovative biopharmaceutical companies are able to invest in U.S. R&D, manufacturing facilities and infrastructure. Instead of imposing tariffs, therefore, the Administration should adopt pragmatic solutions and targeted incentives to ensure the United States’ continued security,” wrote Taylor.
In justifying his trade war, Trump has claimed the U.S. economy has been “looted, pillaged, raped, plundered” by global trade agreements.
But Taylor again pushed back on such assertions, writing, “Far from being weakened by international competition, the innovative biopharmaceutical industry has demonstrated a combination of growth, stability and economic resilience over many years, making the industry a key driver of the U.S. economy.”
Welcome to The Hill’s Health Care newsletter, we’re Nathaniel Weixel, Joseph Choi and Alejandra O’Connell-Domenech — every week we follow the latest moves on how Washington impacts your health.
President Trump has pulled his nomination of Janette Nesheiwat to be U.S. surgeon general and has instead chosen chronic disease entrepreneur Casey Means, a physician with close ties to the “Make American Healthy Again,” or MAHA, movement, as his new pick to fill the role. Nesheiwat’s credentials came into question last month when CBS News reported that records showed she had graduated from the American University …
The Trump administration on Wednesday announced a partnership between the National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) that will focus on research looking into the “root causes of autism spectrum disorder.” According to a press release, the partnership will enable research into claims data, electronic medical records and consumer wearables. The announcement comes after …
The Trump administration shuttered the Healthcare Infection Control Practices Advisory Committee (HICPAC), ending three decades of medical advice used by the Centers for Disease Control and Prevention (CDC), according to NBC. A handful of committee members said the CDC delivered the news about HICPAC’s termination to members Friday, NBC reported. The termination took effect more than a month previously, on March 31, according …
CBO: Millions of people could lose insurance under GOP Medicaid options
Millions of people would lose health insurance coverage under various Republican options to cut Medicaid spending to pay for President Trump’s domestic policy agenda, according to an analysis the Congressional Budget Office (CBO) released Wednesday. For instance, a cap on Medicaid spending for beneficiaries in the expansion population would save $225 billion and result in 1.5 million additional people being uninsured …
Republican senators are waving off firebrand Rep. Marjorie Taylor Greene (R-Ga.) from jumping into next year’s Georgia Senate race, voicing concerns … Read more
The Trump administration invoked the state secrets privilege Wednesday to avoid handing over documents in the legal battle over Kilmar Abrego Garcia, … Read more
